Stockscreener 앱 받기
27.80
1.88%
0.465
전일 마감가:
$27.34
열려 있는:
$27.78
하루 거래량:
941.83K
Relative Volume:
0.59
시가총액:
$2.63B
수익:
$522.75M
순이익/손실:
$-558.99M
주가수익비율:
-4.2975
EPS:
-6.47
순현금흐름:
$-439.53M
1주 성능:
+5.55%
1개월 성능:
-23.73%
6개월 성능:
-34.44%
1년 성능:
-37.91%
1일 변동 폭
$27.23
$28.03
1주일 범위
$25.99
$28.52
52주 변동 폭
$25.81
$60.37
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
RARE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
27.82 | 2.58B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.54 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.54 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.67 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.42 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.26 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 개시 | William Blair | Outperform |
| 2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-12-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 개시 | H.C. Wainwright | Buy |
| 2021-08-19 | 개시 | UBS | Sell |
| 2021-07-15 | 개시 | Guggenheim | Neutral |
| 2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-02 | 재개 | Stifel | Buy |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-11-24 | 재개 | Evercore ISI | In-line |
| 2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2019-08-02 | 재개 | Wedbush | Outperform |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 개시 | Goldman | Neutral |
| 2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-03-22 | 재개 | Piper Jaffray | Overweight |
| 2018-02-21 | 재확인 | Stifel | Buy |
| 2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 개시 | Credit Suisse | Outperform |
| 2017-12-05 | 재확인 | Barclays | Equal Weight |
| 2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks - Benzinga
Ultragenyx Pharma stock rating initiated at Buy by H.C. Wainwright - Investing.com
What is the dividend policy of Ultragenyx Pharmaceutical Inc. stockCapitalize on proven investment strategies - jammulinksnews.com
Ultragenyx Pharmaceutical Inc. stock trendline breakdownChart Scanner for Swing Trade Timing - Newser
How hedge fund analytics apply to Ultragenyx Pharmaceutical Inc. stockReal-Time AI Generated Market Forecast - Newser
Visual trend scoring systems applied to Ultragenyx Pharmaceutical Inc.Free Growth Focused Entry Plan Suggestions - Newser
Ultragenyx Pharmaceutical Inc. stock trendline breakdown Capital Protection Strategy With Risk Analysis - Newser
What catalysts could drive Ultragenyx Pharmaceutical Inc. stock higher in 2025Free Daily Trading Room Entry - jammulinksnews.com
How does Ultragenyx Pharmaceutical Inc. compare to its industry peersMaximize your portfolio’s earning potential - jammulinksnews.com
What institutional investors are buying Ultragenyx Pharmaceutical Inc. stockRapidly expanding wealth - jammulinksnews.com
How strong is Ultragenyx Pharmaceutical Inc. company’s balance sheetGet real-time alerts on high-potential stocks - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionFree Stock Market Practical Discussion Forums - Newser
How Resilient Is Ultragenyx Pharmaceutical Inc. Stock During Economic DownturnsCarefully Curated High Return Stocks - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Will Ultragenyx Pharmaceutical Inc. stock split in the near futureTurbocharged investment results - jammulinksnews.com
What analysts say about Ultragenyx Pharmaceutical Inc. stockFree Trend-Following Techniques - Autocar Professional
Ultragenyx Pharmaceutical Inc. Stock Analysis and ForecastFree Stock Market Return Analysis - Autocar Professional
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Clinical, - openPR.com
What drives Ultragenyx Pharmaceutical Inc. stock priceRapid portfolio appreciation - Autocar Professional
RARE ACTIVE INVESTIGATION: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Ultragenyx Pharmaceutical (RARE) Gets a Complete Response Letter for UX111 - Insider Monkey
Is Ultragenyx Pharmaceutical Inc. a good long term investmentConsistently high returns - jammulinksnews.com
Lost Money on Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Investors in Ultragenyx Pharmaceutical Inc. (RARE) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Lost Money on Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
11 Best All-Time Low Stocks to Buy According to Analysts - Insider Monkey
William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) - MSN
Ultragenyx Grants Restricted Stock Units to New Employees, Expands Workforce and Focus on Rare Diseases. - AInvest
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire about Securities Investigation - ACCESS Newswire
Did You Suffer Losses in Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Shareholders Alert: Investigation Into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Rare Disease Leader Ultragenyx Expands Team with 45,292 Stock Grants to New Hires - Stock Titan
RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm - The Globe and Mail
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.71%
1.39%
자본화:
|
볼륨(24시간):